CLINICAL TRIALS PROFILE FOR ARTEMETHER; LUMEFANTRINE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Artemether; Lumefantrine
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT00203801 ↗ | Combination Antimalarials in Uncomplicated Malaria | Completed | Global Fund | N/A | 2002-01-01 | The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or artemether-lumefantrine. |
| New Combination | NCT00203801 ↗ | Combination Antimalarials in Uncomplicated Malaria | Completed | Medical Research Council, South Africa | N/A | 2002-01-01 | The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or artemether-lumefantrine. |
| New Combination | NCT00203801 ↗ | Combination Antimalarials in Uncomplicated Malaria | Completed | World Health Organization | N/A | 2002-01-01 | The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or artemether-lumefantrine. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Artemether; Lumefantrine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00118794 ↗ | Lapdap and Coartemether for Uncomplicated Malaria | Completed | Medical Research Council | Phase 3 | 2004-09-01 | Lapdap (chlorproguanil-dapsone) is an affordable and effective drug, but patients with glucose-6-phosphate dehydrogenase (G6PD) A- deficiency are more susceptible to the haemolytic effects of the dapsone component of Lapdap; therefore there is a need to evaluate the extent to which the risks associated with the use of the drug in settings without G6PD screening might outweigh the benefits to malaria treatment. The investigators will evaluate, in operational settings, the safety and effectiveness of Lapdap and coartemether (lumefantrine-artemether) for treatment of uncomplicated malaria in patients 6 months to 10 years of age. |
| NCT00118794 ↗ | Lapdap and Coartemether for Uncomplicated Malaria | Completed | National Malaria Control Programme, The Gambia | Phase 3 | 2004-09-01 | Lapdap (chlorproguanil-dapsone) is an affordable and effective drug, but patients with glucose-6-phosphate dehydrogenase (G6PD) A- deficiency are more susceptible to the haemolytic effects of the dapsone component of Lapdap; therefore there is a need to evaluate the extent to which the risks associated with the use of the drug in settings without G6PD screening might outweigh the benefits to malaria treatment. The investigators will evaluate, in operational settings, the safety and effectiveness of Lapdap and coartemether (lumefantrine-artemether) for treatment of uncomplicated malaria in patients 6 months to 10 years of age. |
| NCT00118794 ↗ | Lapdap and Coartemether for Uncomplicated Malaria | Completed | London School of Hygiene and Tropical Medicine | Phase 3 | 2004-09-01 | Lapdap (chlorproguanil-dapsone) is an affordable and effective drug, but patients with glucose-6-phosphate dehydrogenase (G6PD) A- deficiency are more susceptible to the haemolytic effects of the dapsone component of Lapdap; therefore there is a need to evaluate the extent to which the risks associated with the use of the drug in settings without G6PD screening might outweigh the benefits to malaria treatment. The investigators will evaluate, in operational settings, the safety and effectiveness of Lapdap and coartemether (lumefantrine-artemether) for treatment of uncomplicated malaria in patients 6 months to 10 years of age. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Artemether; Lumefantrine
Condition Name
Clinical Trial Locations for Artemether; Lumefantrine
Trials by Country
Clinical Trial Progress for Artemether; Lumefantrine
Clinical Trial Phase
Clinical Trial Sponsors for Artemether; Lumefantrine
Sponsor Name
